Biosynex: Grant received for a rapid preeclampsia test

Biosynex subsidiary Chembio Diagnostic Systems Inc. has received a $0.5 million grant from the Gates Foundation. This funding will support the development of a rapid diagnostic test to predict preeclampsia. This condition affects 2 to 8% of pregnant women and causes 40,000 maternal deaths annually. The WHO considers it a major public health issue, particularly in low- and middle-income countries.

Chembio's rapid test, using a single drop of blood, could provide results in under 20 minutes and be crucial for effectively managing this condition. Javan Esfandiari, president of Chembio, and Professor Vassilis Tsatsaris welcome the Gates Foundation's support for this innovative diagnostic tool, which promises to improve maternal health. This device primarily targets developing countries, where the needs are greatest.